Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Bio-Techne Corp’s stock clocked out at $50.42, up 0.54% from its previous closing price of $50.15. In other words, the price has increased by $0.54 from its previous closing price. On the day, 1.9 million shares were traded. TECH stock price reached its highest trading level at $50.58 during the session, while it also had its lowest trading level at $49.56.
Ratios:
To gain a deeper understanding of TECH’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 48.73 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 29.96. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 3.46. In the meantime, Its Debt-to-Equity ratio is 0.23 whereas as Long-Term Debt/Eq ratio is at 0.22.
On July 09, 2025, TD Cowen started tracking the stock assigning a Buy rating and target price of $65.
On May 30, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $59.Wells Fargo initiated its Overweight rating on May 30, 2025, with a $59 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Jun 09 ’25 when Herr Amy E. sold 1,280 shares for $49.77 per share. The transaction valued at 63,705 led to the insider holds 1,976 shares of the business.
JOSHUA MOLHO bought 1,280 shares of TECH for $63,705 on Jun 09 ’25. On Feb 14 ’25, another insider, Herr Amy E., who serves as the Director of the company, sold 1,860 shares for $65.96 each. As a result, the insider received 122,691 and left with 1,976 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, TECH now has a Market Capitalization of 7904192512 and an Enterprise Value of 8092585472. As of this moment, Bio-Techne’s Price-to-Earnings (P/E) ratio for their current fiscal year is 111.13, and their Forward P/E ratio for the next fiscal year is 22.31. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 9.15. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.48 while its Price-to-Book (P/B) ratio in mrq is 3.92. Its current Enterprise Value per Revenue stands at 6.635 whereas that against EBITDA is 34.732.
Stock Price History:
The Beta on a monthly basis for TECH is 1.47, which has changed by -0.29757595 over the last 52 weeks, in comparison to a change of 0.19554341 over the same period for the S&P500. Over the past 52 weeks, TECH has reached a high of $80.95, while it has fallen to a 52-week low of $46.01. The 50-Day Moving Average of the stock is -3.37%, while the 200-Day Moving Average is calculated to be -18.37%.
Shares Statistics:
It appears that TECH traded 2.43M shares on average per day over the past three months and 2786180 shares per day over the past ten days. A total of 156.77M shares are outstanding, with a floating share count of 154.97M. Insiders hold about 1.15% of the company’s shares, while institutions hold 102.88% stake in the company. Shares short for TECH as of 1752537600 were 6530665 with a Short Ratio of 2.68, compared to 1749772800 on 6139163. Therefore, it implies a Short% of Shares Outstanding of 6530665 and a Short% of Float of 4.79.
Dividends & Splits
With its trailing 12-month dividend rate of 0.0, TECH has a forward annual dividend rate of 0.32. Against a Trailing Annual Dividend Yield of 0.0The stock’s 5-year Average Dividend Yield is 0.41. The current Payout Ratio is 69.57% for TECH, which recently paid a dividend on 2025-05-19 with an ex-dividend date of 2025-08-18. Stock splits for the company last occurred on 2022-11-30 when the company split stock in a 4:1 ratio.
Earnings Estimates
The performance of Bio-Techne Corp (TECH) in the stock market is under the watchful eye of 13.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.46, with high estimates of $0.49 and low estimates of $0.43.
Analysts are recommending an EPS of between $2.07 and $1.91 for the fiscal current year, implying an average EPS of $2.02. EPS for the following year is $2.28, with 13.0 analysts recommending between $2.44 and $2.14.
Revenue Estimates
In the current quarter, 13 analysts expect revenue to total $292.7M. It ranges from a high estimate of $298M to a low estimate of $286.2M. As of the current estimate, Bio-Techne Corp’s year-ago sales were $289.46MFor the next quarter, 13 analysts are estimating revenue of $300.46M. There is a high estimate of $309.5M for the next quarter, whereas the lowest estimate is $295.3M.
A total of 14 analysts have provided revenue estimates for TECH’s current fiscal year. The highest revenue estimate was $1.26B, while the lowest revenue estimate was $1.23B, resulting in an average revenue estimate of $1.25B. In the same quarter a year ago, actual revenue was $1.22BBased on 14 analysts’ estimates, the company’s revenue will be $1.34B in the next fiscal year. The high estimate is $1.42B and the low estimate is $1.3B.
